Related Experiment Videos
Clinical status of carboplatin
R Canetta1, C Franks, L Smaldone
1Bristol-Myers Company, Pharmaceutical Research and Development Division, Wallingford, Connecticut.
Oncology (Williston Park, N.Y.)
|July 1, 1987
Abstract:
Carboplatin, a cisplatin derivative, shows promise of being an effective weapon against ovarian, cervical, and small-cell lung cancer, as well as epidermoid cancer of the head and neck, with fewer toxic effects than cisplatin. It has successfully completed phase III investigation and clinical trials continue.